CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...